 BOTHELL, Wash., Sept. 29, 2021 GLOBE NEWSWIRE -- Athira Pharma, Inc. NASDAQ: ATHA, a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that updates and baseline data from two ongoing Phase 2 and Phase 23 clinical trials of its lead development candidate ATH-1017, a novel small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor HGF and its receptor MET, in mild-to-moderate Alzheimers disease, will be presented as an oral presentation at the upcoming 2021 Clinical Trials on Alzheimers Disease CTAD conference taking place Nov. 9-12, 2021 both virtually and in-person in Boston. 